NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said